Breaking Down Fulcrum Therapeutics: A Shift in Analyst Sentiments

Recent ratings from seven analysts have revealed a wide range of perspectives on Fulcrum Therapeutics (NASDAQ:FULC), with views spanning from bullish to bearish. The past three months have seen these analysts release their ratings, showcasing the shifting sentiments over the past 30 days and comparing them to previous months.

A breakdown of the ratings is presented in the table below:

Ratings Summary

Bullish: 1, Somewhat Bullish: 1, Indifferent: 4, Somewhat Bearish: 1, Bearish: 0

Over the past month, we have seen significant changes in analyst ratings. Last 30 days: 0 Up, 1 Down, 0 Initiated, compared to 1 month ago: 0 Up, 1 Down, 0 Initiated, and 2 months ago: 0 Up, 3 Down, 0 Initiated.

Analysts' 12-month price targets have also provided insights, with an average target of $9.0, a high estimate of $23.00, and a low estimate of $2.00. A notable 42.57% drop is evident in the current average compared to the previous average price target of $15.67.

A comprehensive examination of how financial experts perceive Fulcrum Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Actions

Andrew Fein (HC Wainwright & Co.) lowered the price target to $4.00 from $17.00, maintaining a Neutral rating. Joseph Schwartz (Leerink Partners) announced a Market Perform rating with a $4.00 price target. Tazeen Ahmad (B of A Securities) initially lowered the price target to $2.00 from $10.00, giving an Underperform rating. However, he later raised the price target to $10.00 from $5.00, changing the rating to Neutral.

Dae Gon Ha (Stifel) lowered the price target to $3.00 from $22.00, maintaining a Hold rating. Andrew Fein (HC Wainwright & Co.) maintained a Buy rating, keeping the price target at $17.00. Kristen Kluska (Cantor Fitzgerald) also maintained an Overweight rating, with the price target remaining at $23.00.

Key Insights

Analysts' actions and recommendations often reflect changing market conditions and company performance. They assess various factors, including financial reports, industry trends, and growth prospects, before making their conclusions.

As the ratings and price targets continue to fluctuate, investors and analysts alike will be closely monitoring Fulcrum Therapeutics' performance and future developments. The dramatic price cuts and mixed reviews demonstrate the complexity and volatility of the market, emphasizing the importance of staying informed and up-to-date with the latest news and trends.